Exhibit 99.1 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – August 1, 2024 – Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2024, and provided business highlights. ...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2024, and provided business highlights. "In the second quarter, our Enzyme Transport Vehicle franchise gained additional momentu ...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2024, and provided business highlights. "In the second quarter, our Enzyme Transport Vehicle franchise gained additional momentu ...

Denali Therapeutics Inc. (DNLI) shares ended the last trading session 9.7% higher at $23.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.2% loss over the past four weeks. The FDA recently selected its experimental candidate, DNL126, in support of clinical trials advancing the rare disease therapeutics Pilot Program. The pipeline progress has been encouraging as well. Earnings and revenue growth expectations c ...

The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago. These discoveries and more are enabling the FDA and other agencies to classify aging as a curable illness. This change might hasten the authorization of anti-aging medications. As the number of individuals more than 60 rises to 2.1 billion by 2025, longevity stocks will fare well as biotechnology advances like artificia ...

Denali and Sanofi are also developing SAR443122/DNL758 (eclitasertib), a peripheralRIPK1 inhibitor, for the treatment of ulcerative colitis. The cash position is sound as well. Cash, cash equivalents and marketable securities totaled approximately $1.43 billion as of Mar 31, 2024. In February, Denali announced the completion of a private investment in public equity (PIPE) financing with gross proceeds of $500 million. Denali's pipeline potential and the successful development of any of these candidates will ...

This company is expected to post quarterly loss of $0.69 per share in its upcoming report, which represents a year-over-year change of -153.1%. Revenues are expected to be $24.23 million, down 91.8% from the year-ago quarter. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Denali owns an impressive pipeline of targeted therapeutic candidates for neurodegenerative diseases and its recent pipeline progress has been encour ...

Collaboration leverages ProFound's proprietary ProFoundry™ Platform to identify potential novel protein therapeutics from the expanded human proteome Pioneering Medicines, Flagship's in house drug discovery and development unit, is responsible for leading the partnership with Pfizer, including driving the exploration process to rapidly surface potential drug development programs built on Flagship's diverse bioplatforms and modalities. Under this collaboration, ProFound will deploy its proprietary ProFoundry ...

It has been about a month since the last earnings report for Denali Therapeutics Inc. (DNLI) . Shares have added about 15.6% in that time frame, outperforming the S&P 500. Denali Q1 Earnings Miss, Pipeline Progress in Focus The year-over-year narrower loss was due to a decline in operating expenses. Quarter in Detail Research and development expenses fell 17% to $107 million in the quarter. The decrease was mainly attributable to a decrease in ETV:IDS program external expenses year. As of Mar 31, 2024, cash ...

Since DNL126 has been selected as a START participant, it can interact with the FDA frequently. The company expects the increased level of engagement from the FDA, to facilitate alignment on the most efficient development path to ultimately support a marketing application for DNL126 in MPS IIIA. Please note that Denali has another candidate in its pipeline, tividenofusp alfa (DNL310), which is engineered to cross the BBB via receptor-mediated transcytosis into the brain. The candidate is being developed as ...